GitLab shares are gaining traction, driven by robust AI-powered DevSecOps adoption and an expanding clientele.

The quiet month of January is the ideal time to dive into some poetry. This curated collection – out now – features the works ...

Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for the treatment of diabetic macular edema in October ...

Regeneron has bought Oxular, a UK-based specialist in retinal diseases, in a move that bolsters its already strong position ...